Boston Scientific's (BSX) Buy Rating Reaffirmed at Needham & Company LLC

Key Points

• Needham & Company LLC has reaffirmed a "buy" rating for Boston Scientific (BSX) and set a target price of $121.00, indicating a potential upside of 14.88% from the current price.
• Boston Scientific reported strong quarterly earnings, with earnings per share of $0.75, beating estimates and showing a revenue increase of 22.8% compared to the same quarter last year.
• Insider trading activity includes significant sales by executives, with Joseph Fitzgerald selling shares worth over $5.2 million, resulting in a 21.90% decrease in his ownership of the stock.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They currently have a $121.00 target price on the medical equipment provider's stock. Needham & Company LLC's target price would indicate a potential upside of 14.88% from the stock's current price.

BSX has been the topic of a number of other research reports. Leerink Partners assumed coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective on the stock. Citigroup reiterated a "buy" rating and issued a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Barclays increased their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Finally, Raymond James Financial increased their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $118.04.

Boston Scientific Trading Down 2.6%

Shares of Boston Scientific stock opened at $105.32 on Thursday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a market capitalization of $156.06 billion, a price-to-earnings ratio of 62.69, a PEG ratio of 2.60 and a beta of 0.65. The firm's 50 day simple moving average is $104.88 and its two-hundred day simple moving average is $102.24.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently modified their holdings of BSX. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its stake in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE lifted its stake in shares of Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after buying an additional 1,439 shares in the last quarter. Gotham Asset Management LLC lifted its stake in shares of Boston Scientific by 43.7% in the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock worth $1,021,000 after buying an additional 3,475 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Boston Scientific by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 321,764 shares of the medical equipment provider's stock worth $28,740,000 after purchasing an additional 18,146 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.